Original paperQuality of life in oncology practice: Prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy
References (26)
- et al.
Evaluation of quality of life in patients receiving treatment for advanced breast cancer
Lancet
(1976) - et al.
Measuring the quality of life of cancer patients: a concise QL- index for use by physicians
J Chron Dis
(1981) - et al.
On the receiving end. III: Measurement of quality of life during cancer chemotherapy
Ann Oncol
(1990) - et al.
Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic melanoma
Eur J Cancer
(1993) - et al.
Psychological response to breast cancer and 15-year outcome [letter]
Lancet
(1990) - et al.
The effect of psychosocial treatment on survival of patients with metastatic breast cancer
Lancet
(1989) - et al.
The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology
J Natl Cancer Inst
(1993) - et al.
Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer
Br Med J
(1977) - et al.
On the receiving end, II: Linear analogue self assessment in the evaluation of quality of life of cancer patients
Eur J Cancer Clin Oncol
(1983) - et al.
Improving the quality of life in advanced breast cancer. A comparison of continuous and intermittent treatment strategies
N Engl J Med
(1987)
A randomized trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for patients with metastatic breast cancer
J Clin Oncol
(1988)
Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial
Melanoma Res
(1993)
Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life
Br J Cancer
(1993)
Cited by (276)
Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E<sup>2</sup>-RADIatE OligoCare cohort
2024, Clinical and Translational Radiation OncologyHead and neck cancer predictive risk estimator to determine control and therapeutic outcomes of radiotherapy (HNC-PREDICTOR): development, international multi-institutional validation, and web implementation of clinic-ready model-based risk stratification for head and neck cancer
2023, European Journal of CancerThe Impact of Disease Progression on Health-Related Quality of Life Outcomes in Patients With Oligometastatic Disease at 12 Months Post Stereotactic Body Radiation Therapy
2022, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :Interventions such as SBRT may prevent disease progression and possibly improve survival2,3 but at a cost of worsening overall HRQOL. Prior prospective cancer studies, particularly in the metastatic setting have found some HRQOL measurement tools to be predictive of outcomes, including survival.4-6 Disease progression and progression free survival (PFS) are the most common primary endpoints7 in completed and ongoing oligometastatic clinical trials.
Copyright © 1997 Published by Elsevier Ltd.